
Zomedica Corp. (ZOM)
$
0.1
Key metrics
Financial statements
Free cash flow per share
-0.0200
Market cap
95.3 Million
Price to sales ratio
3.5675
Debt to equity
0.0102
Current ratio
10.8222
Income quality
0.3831
Average inventory
5.5 Million
ROE
-0.2816
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Zomedica Corp., a veterinary health company centered on addressing the unmet needs of clinical veterinarians, develops innovative products for companion animals. The company's operational efficiency is highlighted by its EBITDA ratio of -1.17. For the fiscal year 2024 Zomedica reported a gross profit of $17,318,000.00 underscoring its profitability from core operations. The company faced an income tax expense of -$1,331,000.00 reflecting its tax obligations, while also reporting depreciation and amortization expenses of $6,298,000.00 which indicate the wear and tear on its assets. With advancements in veterinary diagnostics, Zomedica has made significant strides through its TRUFORMA platform, providing point-of-care diagnostic products for dogs and cats. Moreover, the PulseVet service addresses various musculoskeletal issues in both horses and small animals. Collaborative agreements with Celsee, Inc. aim to develop and market liquid biopsy assays for cancer detection in companion animals, while a partnership with Seraph Biosciences, Inc. focuses on creating a novel pathogen detection system. Originally named Zomedica Pharmaceuticals Corp., the company rebranded to Zomedica Corp. in October 2020 and has its headquarters in Ann Arbor, Michigan, founded in 2015. In the stock market, Zomedica's shares are appealing to budget-conscious investors, priced affordably at $0.10. The stock's high average trading volume of 8,541,418.00 indicates strong liquidity, making it an attractive choice for potential investors. With a market capitalization of $95,349,137.00 Zomedica is classified as a small-cap player within the broader financial landscape. This positioning is significant, as Zomedica is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing meaningfully to the market's overall dynamic. Additionally, the company operates within the Healthcare sector, driving ongoing innovation and growth, which further enhances its potential for future developments in veterinary health care.
Analysts predict Zomedica Corp. stock to fluctuate between $0.02 (low) and $0.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-03-04, Zomedica Corp.'s market cap is $95,349,137, based on 979,950,016 outstanding shares.
Compared to Eli Lilly & Co., Zomedica Corp. has a Lower Market-Cap, indicating a difference in performance.
To buy Zomedica Corp. (ZOM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ZOM. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $25,186,000 | EPS: -$0.04 | Growth: 102.30%.
Visit https://www.zomedica.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $0.80 (2021-08-26) | All-time low: $0.09 (2025-03-04).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

seekingalpha.com
Zomedica Corp. (OTC:ZOMDF) Q3 2025 Earnings Call November 21, 2025 4:00 PM EST Company Participants Larry Heaton - President, CEO & Director Mike Zuehlke - Senior VP of Finance & Corporate Controller Presentation Unknown Executive Before we begin, I want to remind current and potential investors that we will be making various remarks about future expectations, plans and prospects that are considered forward-looking statements. There are risks that actual results may differ from these statements.

accessnewswire.com
November session to provide strategic context for Zomedica's product platforms featured in the previous Fourth Friday at Four Webinars ANN ARBOR, MI / ACCESS Newswire / November 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced a special session of its "Fourth Friday at Four" investor webinar series. To accommodate the holiday calendar, this month's webinar will be held on the third Friday-November 21, 2025 at 4:00 p.m.

accessnewswire.com
Certification enhances global market readiness, reinforces quality systems, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire / November 6, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that it has earned ISO 13485:2016 certification for its manufacturing and distribution operations in Plymouth, Minnesota and Roswell, Georgia. This milestone further cements Zomedica's commitment to quality, compliance, and global market readiness.

accessnewswire.com
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in the multi-billion-dollar global veterinary diagnostics and therapeutic device markets ANN ARBOR, MI / ACCESS Newswire / October 14, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that it has entered into an expanded distribution agreement with Grovet b.v., a leading equine health company based in the Netherlands.
accessnewswire.com
Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions ANN ARBOR, MI / ACCESS Newswire / September 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, announced today that it has expanded its distribution agreement with UXR Inc., a leading Canadian animal health company focused on supporting the needs of veterinarians across Canada. Under the expanded agreement, UXR will become: Exclusive distributor of Zomedica's PulseVet® system in Canada and co-exclusive distributor of the system's consumable Trode accessories.

accessnewswire.com
Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading point-of-care solutions ANN ARBOR, MI / ACCESS Newswire / September 3, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced a new distribution partnership in the United Kingdom with Pioneer Veterinary Products Limited, one of the region's most respected veterinary distributors. The agreement begins with the distribution of Zomedica's TRUFORMA® diagnostic platform throughout England, Scotland, Wales, and Northern Ireland, with the introduction of VETGuardian® remote monitoring technology planned at a later stage.

accessnewswire.com
New agreement brings innovative shock wave, tPEMF therapy, monitoring, and bleeding control solutions to more than 2,200 member clinics nationwide ANN ARBOR, MI / ACCESS Newswire / August 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, announced today a new strategic partnership with VerticalVet, one of the veterinary industry's most respected Group Purchasing Organizations (GPOs), supporting over 2,600 independent veterinary practices across the United States. This two-year agreement establishes Zomedica as a preferred provider of advanced veterinary solutions to the VerticalVet membership network.

globenewswire.com
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

accessnewswire.com
Engaging Sessions to Highlight Game-Changing Technologies, Expert Insights, and Growth Opportunities in Animal Health Featuring Zomedica Products ANN ARBOR, MI / ACCESS Newswire / May 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of a new monthly webinar series designed to highlight its innovative product portfolio, introduce key personnel, showcase manufacturing capabilities, and educate investors and strategic partners on the company's long-term growth strategy. This exclusive webinar series scheduled for the fourth Friday of every month beginning May 23rd, offers a front-row seat to Zomedica's game-changing technologies and strategic vision, providing veterinarians, investors, and industry leaders with an unparalleled opportunity to stay ahead of the curve in animal healthcare.

zacks.com
Zomedica Corp. (ZOMDF) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.01 per share a year ago.
See all news